{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T07:57:00Z","timestamp":1783238220969,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.medcli.2016.12.018","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T14:15:43Z","timestamp":1485958543000},"page":"277-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Eliminaci\u00f3n de la hepatitis C en Espa\u00f1a: adaptaci\u00f3n de un modelo matem\u00e1tico de salud p\u00fablica partiendo del plan estrat\u00e9gico para el abordaje de la hepatitis C en el Sistema Nacional de Salud"],"prefix":"10.1016","volume":"148","author":[{"given":"Mar\u00eda","family":"Buti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Turnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Javier","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homie","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.medcli.2016.12.018_bib0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J Viral Hepat."},{"key":"10.1016\/j.medcli.2016.12.018_bib0160","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology."},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2016.12.018_bib0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"Cornberg","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.medcli.2016.12.018_bib0170","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/MEG.0b013e328313139d","article-title":"Hepatitis C and hepatitis B-related mortality in Spain","volume":"21","author":"Garcia-Fulgueiras","year":"2009","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2016.12.018_bib0175","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan estrat\u00e9gico para el abordaje de la hepatitis C en el sistema nacional de salud. Madrid, 21 de mayo de 2015."},{"key":"10.1016\/j.medcli.2016.12.018_bib0180","unstructured":"AASLD-IDSA. HCV guidance: Recommendations for testing, managing, and treating adults infected with hepatitis C virus. Updated: February 24, 2016. Changes made: April 7, 2016 [consultado 8 Abr 2016]. Disponible en: http:\/\/www.hcvguidelines.org"},{"key":"10.1016\/j.medcli.2016.12.018_bib0185","unstructured":"Minist\u00e8re des Affaires sociales et de la Sant\u00e9. Direction G\u00e9n\u00e9rale de la Sant\u00e9. Plan national de lutte contre les H\u00e9patites B et C 2009-2012 [consultado 8 Abr 2016]. Disponible en: www.sante-sports.gouv.fr"},{"key":"10.1016\/j.medcli.2016.12.018_bib0190","unstructured":"Scottish Government. Hepatitis C Action Plan for Scotland: Phase II (May 2008-March 2011). Edinburgh: Scottish Government; 2008 [consultado 8 Abr 2016]. Disponible en: http:\/\/www.scotland.gov.uk\/Publications\/2008\/05\/13103055\/0"},{"key":"10.1016\/j.medcli.2016.12.018_bib0195","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Nota de prensa. M\u00e1s de 40.000 pacientes de hepatitis C han recibido tratamiento en Espa\u00f1a desde el 1 de enero de 2015 con medicamentos de \u00faltima generaci\u00f3n [consultado 17 Mar 2016]. Disponible en: http:\/\/www.msssi.gob.es\/gabinete\/notasPrensa.do?id=3909"},{"key":"10.1016\/j.medcli.2016.12.018_bib0200","unstructured":"Distribuci\u00f3n por sexo y tramos de edad, actualizados (INE). INEbase\/Cifras de poblaci\u00f3n y censos demogr\u00e1ficos\/Proyecciones de poblaci\u00f3n. Serie 2014-2064. Publicado: 28\/10\/2014 [consultado 15 Sep 2015]. Disponible en: http:\/\/www.ine.es\/inebaseDYN\/propob30278\/propob_inicio.htm"},{"key":"10.1016\/j.medcli.2016.12.018_bib0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jhep.2014.05.008","article-title":"Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios","volume":"61","author":"Harris","year":"2014","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2016.12.018_bib0210","first-page":"90","article-title":"Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: Cross-sectional study","volume":"119","author":"Sol\u00e0","year":"2002","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2016.12.018_bib0215","unstructured":"Generalitat de Catalunya, Departament de Salut. Activities Report: Year 2010. Advisory Council on Drug Treatment of Viral Hepatitis. Barcelona, Spain: Generalitat de Catalunya, Departament de Salut; 2011."},{"key":"10.1016\/j.medcli.2016.12.018_bib0220","first-page":"145","article-title":"Profiles and clinical management of hepatitis C patients in Spain: disHCovery study","volume":"28","author":"Buti","year":"2015","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.medcli.2016.12.018_bib0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2007.07.031","article-title":"Hospital admission is a relevant source of hepatitis C virus acquisition in Spain","volume":"48","author":"Mart\u00ednez-Bauer","year":"2008","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2016.12.018_bib0230","unstructured":"Instituto Nacional de Estad\u00edstica. Fen\u00f3menos demogr\u00e1ficos. Movimiento natural de la poblaci\u00f3n. 2 de diciembre de 2015 [consultado 28 Ene 2016]. Disponible en: http:\/\/www.ine.es\/jaxi\/menu.do?type=pcaxis&path=%2Ft20%2Fe306&file=inebase&L=0"},{"key":"10.1016\/j.medcli.2016.12.018_bib0235","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-8-8","article-title":"A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo","volume":"8","author":"Bjornaas","year":"2008","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.medcli.2016.12.018_bib0240","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1537-2995.2008.01881.x","article-title":"Survival after blood transfusion","volume":"48","author":"Kamper-Jorgensen","year":"2008","journal-title":"Transfusion."},{"key":"10.1016\/j.medcli.2016.12.018_bib0245","unstructured":"Organizaci\u00f3n Nacional de Trasplantes. Registro espa\u00f1ol de trasplante hep\u00e1tico. Memoria de resultados 2014 [consultado 21 Dic 2015]. Disponible en: http:\/\/www.ont.es\/infesp\/Paginas\/RegistroHepatico.aspx"},{"key":"10.1016\/j.medcli.2016.12.018_bib0250","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S0168-8278(16)00188-4","article-title":"Effectiveness and safety of sofosbuvir\/ledipasvir treatment for monoinfected genotype 1 HCV patients in real-life clinical practice: Results from Spanish Hepa-C cohort","volume":"64","author":"Crespo","year":"2016","journal-title":"J Hepatol."},{"issue":"Suppl","key":"10.1016\/j.medcli.2016.12.018_bib0255","first-page":"225A","article-title":"Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program","volume":"62-1","author":"Welzel","year":"2015","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2016.12.018_bib0260","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/S0168-8278(16)01535-X","article-title":"SOF\/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: An integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies. SAT-195","volume":"64","author":"Agarwal","year":"2016","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2016.12.018_bib0265","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol."},{"issue":"Suppl 6","key":"10.1016\/j.medcli.2016.12.018_bib0270","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2334-14-S6-S7","article-title":"The successful implementation of Scotland's Hepatitis C Action Plan: What can other European stakeholders learn from the experience? A Scottish voluntary sector perspective","volume":"14","author":"Wylie","year":"2014","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.medcli.2016.12.018_bib0275","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1503\/cmaj.140711","article-title":"Cost-effectiveness of screening for hepatitis C in Canada","volume":"187","author":"Wong","year":"2015","journal-title":"CMAJ."},{"key":"10.1016\/j.medcli.2016.12.018_bib0280","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1155\/2014\/140864","article-title":"With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access to these drugs?","volume":"28","author":"Peltekian","year":"2014","journal-title":"Can J Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2016.12.018_bib0285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"Najafzadeh","year":"2015","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.medcli.2016.12.018_bib0290","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/civ221","article-title":"Getting smart in how we pay for HCV drugs: KAOS vs CONTROL","volume":"61","author":"Saag","year":"2015","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2016.12.018_bib0295","first-page":"417","article-title":"The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms","volume":"73","author":"Willemse","year":"2015","journal-title":"Neth J Med."},{"key":"10.1016\/j.medcli.2016.12.018_bib0300","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00365521.2014.990505","article-title":"The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies","volume":"50","author":"Duberg","year":"2015","journal-title":"Scand J Gastroenterol."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775316307102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775316307102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T14:28:39Z","timestamp":1536071319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775316307102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0025775316307102"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2016.12.018","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eliminaci\u00f3n de la hepatitis C en Espa\u00f1a: adaptaci\u00f3n de un modelo matem\u00e1tico de salud p\u00fablica partiendo del plan estrat\u00e9gico para el abordaje de la hepatitis C en el Sistema Nacional de Salud","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2016.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}